Antibodies that bind to OX40 and their uses
US12281169B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 30, 2022 |
| Grant date | Apr 22, 2025 |
| Priority date | — |
| Expiry date | Nov 29, 2042 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70578
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.